Prescribing Information | RYPLAZIM (plasminogen, human-tvmh) for HCPs

Prescribing Information For Patients

About RYPLAZIM

What is RYPLAZIM? Efficacy Dosing & administration Ordering RYPLAZIM

About PLGD-1

What is PLGD-1? Lesion locations Most common manifestation Diagnosing PLGD-1

Resources

Cost & support Downloadable resources for HCPs Events calendar Patient testimonials Educational resources Lesion image gallery

Contact a Specialist

Prescribing Information

Loading prescribing information...

Unable to load the PDF viewer. Please use the download button above.

©2025 Kedrion Biopharma Inc. All rights reserved. RYPLAZIM and the RYPLAZIM logo are registered trademarks of Kedrion Biopharma Inc. All other trademarks are the property of their respective owners. December 2025 RY-0266-00-2025

Privacy Notice | Terms of Use | Accessibility Statement | Site Map

This website is intended for US healthcare professionals only.

CANCEL

You are now leaving www.RYPLAZIM-HCP.com

Select OK to continue to the external website or Cancel to stay on this page.

OK

Search

About RYPLAZIM About PLGD-1 Resources

Contact a Specialist

About RYPLAZIM

What is RYPLAZIM? Efficacy

Dosing & administration

How RYPLAZIM works FDA-approved dosing Initiating treatment Long-term management

Ordering RYPLAZIM

Pharmacies & distributors National drug codes Ordering resources

About PLGD-1

What is PLGD-1? Lesion locations Most common manifestation

Diagnosing PLGD-1

Plasminogen activity test Other diagnostic methods Managing specialists

Resources

Cost & support Downloadable resources for HCPs Events calendar Patient testimonials

Educational resources

Lesion image gallery